10-Q: Kairos Pharma Q3 2025: Increased Losses, Funding Efforts

Kairos Pharma, an early-stage biotech, reported increased net losses in Q3 2025 while securing significant financing to advance its oncology immunotherapy and cell therapy programs.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $4,082 thousand from $1,623 thousand in the prior year period.
• Research and development expenses significantly increased to $1,597 thousand for the nine months ended September 30, 2025, compared to $242 thousand in the same period of 2024, primarily due to the Phase 2 prostate cancer trial.
• General and administrative expenses rose to $2,560 thousand for the nine months ended September 30, 2025, from $655 thousand in the prior year, driven by vendor advance amortization and increased insurance costs as a public company.
• Cash and cash equivalents increased to $5,575 thousand as of September 30, 2025, from $1,272 thousand at December 31, 2024, largely due to financing activities.
• The company raised $3,058 thousand from a private financing (PIPE offering) and $3,602 thousand from its Equity Line of Credit (ELOC) during the nine months ended September 30, 2025.
• The company expects its current cash reserves to fund operations for at least 12 months from the filing date.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, due to a material weakness related to insufficient review procedures and segregation of duties.

Sentiment

Score: 3

Explanation: While the company successfully raised capital and is advancing clinical trials, the significant increase in net losses, high burn rate, and persistent material weakness in internal controls indicate substantial operational and financial challenges. The 'going concern' dependency on future capital raises adds to the negative sentiment, despite the positive cash position from recent financings.

Positives

• Successfully raised $3,058 thousand from a private financing and $3,602 thousand from an Equity Line of Credit, significantly increasing cash reserves to $5,575 thousand.
• Progressing with clinical trials, including Phase 2 for ENV105 in prostate cancer and Phase 1 for ENV105 in lung cancer and KROS201.
• Secured an amendment with Lonza Sales AG for the manufacturing preparation of ENV105 antibody for Phase 3 clinical trials, indicating advancement towards later-stage development.
• Streamlined intellectual property structure by transferring key patent licenses from its subsidiary Enviro Therapeutics to Kairos Pharma via novation agreements.

Negatives

• Net loss for the nine months ended September 30, 2025, significantly increased to $4,082 thousand from $1,623 thousand in the prior year period.
• Accumulated deficit grew to $12,897 thousand as of September 30, 2025.
• Operating expenses, particularly R&D and G&A, saw substantial increases, reflecting higher costs associated with clinical trials and public company operations.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, and a material weakness in internal controls over financial reporting persists due to lack of segregation of duties and sufficient review procedures.

Risks

• Ability to continue as a going concern is dependent on attaining and maintaining profitable operations and raising additional capital.
• No assurance that future financing will be available or on satisfactory terms, potentially leading to undue restrictions or substantial dilution to stockholders.
• Successful development and commercialization of product candidates is highly uncertain, with numerous risks related to clinical trials, regulatory approvals, manufacturing, and market acceptance.
• Reliance on third-party manufacturers for clinical supply and commercial manufacturing.
• Ability to obtain and maintain patents, trade secret protection, and regulatory exclusivity.
• Competition with other products in the oncology market.
• Impact of business interruptions (e.g., pandemics) on operations, clinical trials, and supply chain.
• Material weakness in internal controls over financial reporting due to insufficient review procedures and segregation of duties.

Future Outlook

The company expects to continue incurring significant and increasing expenses and operating losses as it advances product candidates through preclinical and clinical development, seeks regulatory approval, expands its intellectual property portfolio, and operates as a public company. It will require substantial additional funding, expecting to finance operations through equity and debt financings, and potential collaboration agreements, strategic alliances, and licensing arrangements until it can generate revenue from product sales. Current cash reserves are expected to fund operations for at least 12 months from the filing date.

Management Comments

• "We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance."
• "Our mission is to advance our portfolio of innovative therapeutics to reverse key mechanisms of therapeutic resistance and immune suppression and transform the way cancer is treated."
• "We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company."
• "We will not generate revenue from product sales unless and until we successfully complete our clinical trials and obtain regulatory approval for our product candidates."
• "We expect to finance our operations through a combination of public or private equity offerings and debt financings and other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements."
• "Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of September 30, 2025."

Industry Context

Kairos Pharma operates in the highly competitive and capital-intensive early-stage biotechnology sector, specifically focusing on oncology immunotherapy and cell therapy. This segment is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and a high risk of failure for product candidates. The company's reliance on external financing and its current lack of revenue are typical for companies at this stage, but the substantial increase in R&D expenses and persistent operating losses highlight the financial demands of advancing multiple clinical programs. The novation agreements suggest a strategic consolidation of intellectual property, which could be a positive step for future development and partnerships.

Comparison to Industry Standards

• The company's financial profile, characterized by significant R&D expenses, operating losses, and an accumulated deficit, is typical for an early-stage biotechnology company focused on drug development, where substantial investment is required before potential revenue generation.
• The reliance on equity and debt financings, such as the ELOC and PIPE offering, is a standard funding mechanism for biotech firms that have not yet brought products to market.
• The increase in R&D expenses due to advancing clinical trials (e.g., Phase 2 for ENV105) aligns with industry norms as drug candidates progress through more costly development stages.
• The identified material weakness in internal controls over financial reporting, particularly regarding segregation of duties, is a common challenge for smaller reporting companies with limited resources, but it is a critical area requiring remediation to meet public company standards.
• The milestone-based license agreements with Cedars-Sinai Medical Center are a common structure for academic-industry collaborations in drug discovery and development.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently the subject of any material legal proceeding. May be involved in future legal proceedings in the ordinary course of business.

Related Party Transactions

• Dr. Ramachandran Murali, Vice President of Research and Development, is also a doctor and scientist at Cedars-Sinai Medical Center and an inventor of three patented technologies licensed from Cedars-Sinai.
• Belair Capital Advisors Inc. (BCA), a long-term investor and advisor, entered into a strategic advisory agreement with the company, receiving a $365 thousand fee and 50,000 RSUs.

Stakeholder Impact

• Shareholders: Experience dilution from recent equity financings (ELOC, PIPE offering) and potential future capital raises. Face increased accumulated deficit and operating losses, but also benefit from increased cash reserves and progress in clinical trials. The material weakness in internal controls could impact investor confidence.
• Employees/Management: Executive officers and directors received RSU grants and cash bonuses, indicating continued compensation and incentives.
• Creditors: Current liabilities decreased, and cash position improved, potentially reducing immediate credit risk, but long-term viability depends on successful product development and further capital.
• Customers (future): Potential future patients could benefit from the development of new oncology treatments, but this is contingent on successful clinical trials and regulatory approval.
• Suppliers/Vendors: Engaged in various vendor agreements for clinical research, biomarker screening, and consulting services, indicating ongoing business relationships.

Next Steps

• Advance current and future product candidates through preclinical and clinical development.
• Manufacture drug product and drug supply for clinical trials.
• Seek regulatory approval for product candidates from the FDA and other foreign regulators.
• Maintain and expand the intellectual property portfolio.
• Hire additional research and development and business personnel.
• Remediate the material weakness in internal controls over financial reporting.
• Continue to raise additional capital through equity and debt financings or strategic agreements.
• Complete the 13 stages of the Lonza Amendment for ENV105 antibody manufacturing preparation.
• RSUs granted on October 8, 2025, will vest in full on October 8, 2026.

Key Dates

Recommendation

Kairos Pharma is an early-stage biotechnology company with no current revenue and significant operating losses, which is typical for its stage. While the company successfully raised substantial capital through an ELOC and PIPE offering, significantly improving its cash position and extending its liquidity runway to at least 12 months, the increased net losses and R&D expenses reflect a high burn rate. The progress in advancing clinical trials for ENV105 and KROS201, along with strategic IP consolidation and manufacturing agreements, are positive indicators of development. However, the persistent material weakness in internal controls over financial reporting and the inherent high risks associated with drug development, including the uncertainty of regulatory approvals and future financing, warrant a cautious approach. The stock is a speculative investment based on future clinical success, and while recent financing provides stability, the fundamental challenges remain. Therefore, a 'hold' recommendation is appropriate for existing investors, acknowledging both the progress and the significant risks, while new investors should approach with extreme caution.

Keywords

Biotechnology, Oncology, Immunotherapy, Cell Therapy, Clinical Trials, SEC Filing, 10-Q, Kairos Pharma, KAPA, ENV105, KROS201, Drug Development, Financial Results, Capital Raise, Going Concern, Internal Controls, Patent Licensing